NCT00616694已完成4 期
A Randomized Multicenter Parallel Group Study to Determine if Knowledge of Baseline Vertebral Fracture Prevalence (as Determined by Hologic IVA) and Bone Turnover Marker Determinations Improves Persistence With Actonel 5mg Daily Therapy in Subjects Receiving Chronic Glucocorticoid Therapy
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 248
- 试验地点
- 1
- 主要终点
- Determine whether subject knowledge of baseline vertebral fracture prevalence and awareness of results of bone turnover marker (BTM)determinations would result in an increase in persistence with Actonel 5 mg daily therapy
研究概览
简要总结
To evaluate the effect of subject knowledge of their disease status on persistence in subjects receiving Actonel 5 mg daily over a 12-month period for the prevention and treatment of GIO.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with a variety of rheumatologic, pulmonary, and skin conditions.
- •Subjects were to be on oral glucocorticoids with a mean daily dose of greater than or equal to 5.0 mg prednisone (or its equivalent) and were expected (although not required) to remain on a daily dose of greater than or equal to 5.0 mg prednisone (or its equivalent) for 12 months after the study started.
- •Women must have been at least one year post-menopausal or surgically sterile.
- •Subjects must have had evaluable BMD site at the lumbar spine (LS) and proximal femur.
排除标准
- •Subject's unwillingness to take Vitamin D, calcium supplements or study medication
- •A history of cancer: any history of cancer within the past 5 years. Relatively benign skin malignancies, such as basal cell carcinoma or squamous cell carcinoma, are not an exclusion if the subject has been in remission for at least 6 months prior to enrollment.
- •A history of hyperparathyroidism, hyperthyroidism or osteomalacia or other metabolic bone disease within one year prior to enrollment
- •History of alcohol or drug dependence within one year of enrollment
- •A history of using any of the following medications within 6 months of starting study drug: Estrogen or estrogen-related drugs (tamoxifen, raloxifene, tibolone); low dose vaginal estrogen (estradiol < 0.2 mg/day, estropipate < 1.5 mg/day) will be allowed,Anabolic steroids,Parathyroid hormone
- •A history of using any of the following medications within 1 month of starting study drugor for more than 1 month within 6 months prior to study entry: Calcitonin,Vitamin D supplements (>1000 IU per day),Calcitriol (>1.5mcg/week)
- •A history of using any of the following medications within 6 months of starting study drug or for more than 14 days within 1 year prior to study entry: Any bisphosphonate,Fluoride (> 10 mg per day),Estrogen implant,Deflazacort
- •Have received a depot injection of > 10,000 IU Vitamin D in the past 12 months
- •Have a documented history of an abnormal or allergic reaction to bisphosphonates
- •History of recurrent nephrolithiasis or a history of one episode of nephrolithiasis within 5years of study entry
- •Severe renal impairment (creatinine clearance of <30 mL/min)
- •Subjects on steroid therapy for transplantation
- •Subjects on oral glucocorticoids for >8 weeks but <6 months at screening
- •History of hypersensitivity to the investigational product or to drugs with similar chemical structures
- •Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult
- •Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
结局指标
主要结局
Determine whether subject knowledge of baseline vertebral fracture prevalence and awareness of results of bone turnover marker (BTM)determinations would result in an increase in persistence with Actonel 5 mg daily therapy
时间窗: 12 months
次要结局
- Evaluate relationship between prevalence of vertebral fractures and duration of prior steroid therapy, amount of prior steroid therapy, and diagnosis of disease for which steroids were used(12 months)
- To evaluate the correlation between baseline vertebral fracture prevalence and subject persistence with Actonel 5 mg daily(12 months)
- Evaluate influence of Actonel 5 mg on BTM determinations and bone mineral density(BMD) at study finish relative to baseline(12 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Study to Assess Persistence, Adherence and Changes in Disease Activity in the Children Population of Juvenile Arthritis Patients Treated With Adalimumab (HUMIRA®)Polyarticular Juvenile ArthritisNCT03383263AbbVie70
招募中
不适用
Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INOBacterial InfectionsViral InfectionFungal InfectionInfectionsAcute Lymphoblastic Leukemia, AdultAcute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic LeukemiaNCT06025682Gruppo Italiano Malattie EMatologiche dell'Adulto158
已完成
不适用
Multicenter Retrospective Observational Study of Acute Myocarditis in KoreaMyocarditis AcuteNCT05933902Samsung Medical Center841
已完成
不适用
of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).Low Density Lipoprotein Cholesterol Goal AchievementNCT00925717AstraZeneca4,045
已完成
不适用
A Clinical Investigation of the Oxford® Meniscal Unicompartmental Knee SystemOsteoarthritisAvascular NecrosisNCT00578994Biomet Orthopedics, LLC388